Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an EGFR targeting moiety reported to be useful for the treatment of cancer particularly, non-small-cell lung cancer (NSCLC).
Alanine-serine-cysteine transporter 2 (ASCT2) is a glutamine (Gln) transporter that is required for cell proliferation and is overexpressed in tumors such as non-small-cell lung cancer (NSCLC). Researchers from China Pharmaceutical University have reported on the discovery and preclinical characterization of a novel series of ASCT2 inhibitors that led to the identification two lead compounds.
Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights. The product, a once-daily oral small-molecule kinase inhibitor of wild-type RET (rearranged during transfection) and oncogenic RET fusions, received accelerated approval in 2020 by the U.S. FDA, under priority review and with orphan drug designation, to treat adults with metastatic RET fusion-positive non-small-cell lung cancer.
Researchers from Zjengzhou University reported on the discovery and preclinical characterization of a novel PROTAC agent aimed at overcoming paclitaxel (Taxol) resistance in non-small-cell lung cancer treatment.
Eli Lilly & Co. has selected FHD-909, a first-in-class oral BRM-selective inhibitor, for clinical development from its 2021 collaboration with Foghorn Therapeutics Inc. Lilly plans to file an IND for FHD-909 in the second quarter of this year. The primary target patient population is BRG1-mutated non-small-cell lung cancer.
Redx Pharma plc has closed its biggest transaction to date, selling a preclinical KRAS inhibitor program to Jazz Pharmaceuticals plc in a potential $880 million deal. Of that, $10 million will be paid up front, with the balance to come in development and commercialization milestones. For any product that makes it to market, Redx will in addition receive tiered mid-single digit percentage royalties.
Researchers at Kanazawa University, Japan, have reported a mixed-glial culture on/in soft substrate (MGS) platform to investigate cancer-glia interactions in vitro. Using this model, they showed that astrocytes favored brain metastasis by promoting metabotropic glutamate mGlu1 receptor (mGluR1) expression in cancer cells and stabilizing EGFR. Eishu Hirata, an associate professor at the Cancer Research Institute, Division of Tumor Cell Biology and Bioimaging at Kanazawa University, and his team
published their work on Feb. 2, 2024, in Developmental Cell.
Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
Oncology company Arrivent Biopharma Inc.’s stock (NASDAQ:AVBP) shot up 11% on Jan. 26, its first day of trading, with its upsized IPO pricing 9.72 million shares at $18 each, raising gross proceeds of $175 million.
